NCT06564324 2026-04-13
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc.
Phase 3 Recruiting
Clinical Trials
12 trialsNCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03947385 2026-01-27
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06563999 2024-12-10
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04084717 2024-07-16
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
University Health Network, Toronto
Phase 2 Recruiting
NCT04322578 2024-06-04
CONFIRM
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting